A tiny, buzzy startup leads the race to produce a coronavirus vaccine that outpaced some world’s largest pharmaceutical companies such as Johnson & Johnson and Sanofi.
That rapid progress was seen on Monday as Moderna confirmed that it had shipped the first lots of its experimental vaccine to the National Health Institutes (NIH). U.S. health department officials have said they plan to start researching the new human Moderna vaccine by April.
The coronavirus Vaccine
While a vaccine candidate is in less than 45 days by the Cambridge, Massachusetts-based biotech, a critical challenge will be to figure out how to scale up their production capacity. Moderna, like most science in the early stages, has no commercial products, or the ability to produce a drug or vaccine in large quantities.
Moderna executives said they are considering “all options” to boost manufacturing, even though they still have a decision to take.
“We are looking at a lot of choices, both internally and externally, for CMO partners, to find out what is the right way forward,”. Said Moderna CEO Stephane Bancel on some earnings call to Wednseday. “When we get a better picture, we’re going to share it.”
CMO stands for contract manufacturing company. Which are firms who help others in the pharmaceutical or biotech industry manufacture their drugs.
Drug industry also has a sense of urgency to identify. And develop vaccines and treatments to stop the coronavirus outbreak which causes the disease called COVID-19. More than 2,700 people are dead and more than 81,000 got the virus.
Moderna’s first clinical trial will test three doses of the cure in healthy adults. Studying to see if the vaccine is safe and creating an immune response. According to a clinicaltrials.gov report, the trial will begin on March 6 and recruit 45 participants.
Thanks to their progress against coronavirus, Moderna’s stock has soared.